Literature DB >> 18000824

Alterations in Barrett's-related adenocarcinomas: a proteomic approach.

DunFa Peng1, Essam A Sheta, Steven M Powell, Christopher A Moskaluk, Kay Washington, Ira L Goldknopf, Wael El-Rifai.   

Abstract

In this study, we applied high-resolution, two-dimensional, gel electrophoresis and matrix-assisted laser desorption/ionization, time-of-flight and tandem mass spectrometry analysis (MALDI TOF MS) to identify novel proteins that are involved in Barrett's tumorigenesis. We analyzed 12 primary tissue samples that included 8 Barrett's-related adenocarcinomas (BA) and 4 normal mucosae samples. Twenty-three spots were consistently altered (>or=2-fold) in at least half of the tumors when compared with all normal samples and thus subjected to further analysis. The MALDI TOF MS analysis demonstrated biologically interesting upregulated proteins such as ErbB3, Dr5 and Cyclin D1 as well as several members of the zinc finger proteins (Znf146, Znf212 and Znf363). Examples of downregulated proteins included Lgi1 and Klf6. We selected four proteins (ErbB3, Dr5, Znf146 and Lgi1) that are novel for BAs for validation using quantitative real-time reverse-transcription PCR on 39 BA tissue samples when compared with normal samples. We demonstrated mRNA upregulation of ERBB3 (51.3%), DR5 (41%) and ZNF146 (30.7%) and downregulation of LGI1 (100%) in BA. We have further validated the protein overexpression of ErbB3, Dr5 and Znf146, using immunohistochemical (IHC) analysis on a tissue microarray that contained 75 BAs and normal gastric and esophageal mucosae samples. BA tissue samples demonstrated overexpression of ErbB3 (42%), Dr5 (90%) and Znf146 (30%) when compared with normal tissues. In conclusion, we have identified and validated several novel proteins that are involved in Barrett's carcinogenesis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18000824     DOI: 10.1002/ijc.23258

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.

Authors:  K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath
Journal:  Dis Esophagus       Date:  2012-03-12       Impact factor: 3.429

Review 2.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management.

Authors:  Brian J Reid; Rumen Kostadinov; Carlo C Maley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

Review 4.  ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors:  William H Fiske; David Threadgill; Robert J Coffey
Journal:  Exp Cell Res       Date:  2008-11-07       Impact factor: 3.905

Review 5.  Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

Authors:  Analisa DiFeo; Goutham Narla; John A Martignetti
Journal:  Mt Sinai J Med       Date:  2009-12

6.  Biomarkers in Barrett's Esophagus.

Authors:  Rhonda F Souza
Journal:  Tech Gastrointest Endosc       Date:  2010-04

7.  Expression of LGI1 Impairs Proliferation and Survival of HeLa Cells.

Authors:  Nadia Gabellini; Valentina Masola
Journal:  Int J Cell Biol       Date:  2009-10-07

Review 8.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Authors:  Brian J Reid; Xiaohong Li; Patricia C Galipeau; Thomas L Vaughan
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 9.  Barrett's oesophagus: an ideal model to study cancer genetics.

Authors:  Massimiliano di Pietro; Rebecca C Fitzgerald
Journal:  Hum Genet       Date:  2009-04-14       Impact factor: 4.132

Review 10.  ErbB receptors in the biology and pathology of the aerodigestive tract.

Authors:  Sarah Morgan; Jennifer R Grandis
Journal:  Exp Cell Res       Date:  2008-08-23       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.